ClinicalTrials.gg
RecruitingNCT06222983Updated Jan 25, 2024

Efficacy and Prognosis of Surgical Intervention in Patients With Carotid Artery Stenosis

An observational study in Carotid Artery Stenting, Carotid Endarterectomy and Carotid Artery Plaque, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-01-25.

Sponsored by Xuanwu Hospital, Beijing · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Carotid Stenosis by Xuanwu Hospital, Beijing — 5 open to participants now, 6 under way, none of them phase 3. Carotid Stenosis · Xuanwu Hospital, Beijing.

Started
2023
the only one that year
Observational
6 of 11
3 open now
Registered
8th of 11
by date

Among the 11 studies in Carotid Stenosis by Xuanwu Hospital, Beijing, this one is the only one that started in 2023, is one of 6 observational ones, and was the 8th registered.

Carotid Stenosis

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

Browse Carotid Stenosis studies →

Open to participants now

5 of the 11 studies in Carotid Stenosis by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Carotid Stenosis by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

This study is a prospective, single center cohort study. By combining pathological examination of carotid atherosclerotic plaque with preoperative imaging examination, we explore the imaging characteristics of high-risk carotid plaque, and explore the effectiveness and safety of different surgical methods (CAS and CEA) for high-risk plaque patients with carotid stenosis.

Read the detailed description

According to the inclusion and exclusion criteria, 100 patients with carotid artery stenosis who underwent surgical reconstruction surgery at our research center were prospectively collected from December 2023 to December 2024. Preoperative laboratory examinations such as blood routine, biochemistry, coagulation, and imaging examinations such as carotid artery ultrasound and TCCD, carotid artery ultrasound contrast, high-resolution MRI, head MRI plain scan, carotid artery CTA or DSA were completed, Based on the comprehensive evaluation of the patient's condition by the supervising physician, the appropriate surgical method (CEA or CAS) is selected. Follow up will be conducted 1/3/6/12 months after surgery to evaluate the incidence of endpoint events (cerebral infarction+all-cause death+postoperative restenosis), MoCA and MMSE cognitive scores, quality of life scores, and severe perioperative complications. At the same time, for patients undergoing CEA surgery, pathological examination of the postoperative carotid artery plaque will be conducted to clarify the nature of the plaque, and combined with imaging examination, the characteristics of high-risk carotid artery plaques will be studied

03

Conditions studied

  • Carotid Artery Stenting
  • Carotid Endarterectomy
  • Carotid Artery Plaque

Browse trials for

Keywords

  • Carotid Revascularization
  • Carotid Artery Stenting
  • Carotid Endarterectomy
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

  1. Patients with spontaneous intracranial hemorrhage within the past 12 months;
  2. Patients with larger intracranial aneurysms (diameter>5mm) that cannot be treated in advance or at the same time;
  3. Patients with chronic complete occlusion without obvious symptoms of cerebral ischemia;
  4. Patients with severe dementia;
  5. Carotid artery opening lesion;
  6. Severe intracranial serial stenosis lesions;
  7. Carotid artery dissection;
  8. Lesions with combined carotid artery aneurysm;
  9. Patients with generally poor physical condition who cannot tolerate surgery;
  10. Coagulation dysfunction, contraindications to heparin and antiplatelet drugs;
  11. Patients who are participating in clinical trials of other drugs or devices but have not reached the trial endpoint;
  12. Pregnant and lactating women;
  13. The researchers believe that patients who are not suitable to participate in this trial.

Inclusion criteria

  1. The patient is aged 45-85 years old;
  2. Symptomatic patients with stenosis degree greater than 50%, or asymptomatic patients with stenosis degree between 70% and 99% (ultrasound, CT or contrast);
  3. Can complete regular follow-up;
  4. The patient is informed and agrees to participate in the study.

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • CEA group

    CEA for atherosclerosis

    Procedure: CEA or CAS

  • CAS group

    CEA for atherosclerosis

    Procedure: CEA or CAS

Interventions

  • ProcedureCEA or CAS

    After the patient is admitted to the hospital, the supervising doctor comprehensively evaluates the patient's general condition and adopts CEA or CAS treatment. The researcher does not provide advice to the supervising doctor and only observes safety and effectiveness

06

What researchers measure

Primary outcomes

  1. Any Periprocedural Stroke, Myocardial Infarction, or Death During1 month Peri-procedural Period, and Postprocedural Ipsilateral Stroke 1 to 12-months.

    Composite of any periprocedural stroke (ipsilateral or contralateral; major or minor), myocardial infarction, or death during1 month peri-procedural period, and postprocedural ipsilateral stroke 1 to 12-months.

    Time frame: 0 to 12 months

  2. Rate of complications

    Rate of complications within 30 days, complications include cranial nerve and peripheral nerve injury, vascular injury, wound complications as neck incision or related to puncture site, and other (such as anesthesia) complications.

    Time frame: 30days

  3. Incidence of ipsilateral stroke

    Incidence of ipsilateral stroke at 30 days follow up

    Time frame: 30days

  4. Incidence of death

    Incidence of death at 30 days follow up.

    Time frame: 30 days

  5. Carotid restenosis rate

    Carotid restenosis was defined as restenosis ≥50% after carotid revascularization, that is, peak systolic velocity ratio (PSVR) ≥2.0 on ultrasound examination.

    Time frame: 3,6,12 months

  6. Improvement in cognitive function

    Cognitive function was assessed by Mini-mental State Examination (MMSE) during follow up.

    Time frame: 0,3,6,12months

  7. Improvement in cognitive function

    Cognitive function was assessed by Montreal Cognitive Assessment Scale (MoCA) during follow up.

    Time frame: 0,3,6,12months

  8. Quality of life rating

    Use VascuQol to evaluate quality of life scores

    Time frame: 30 days

Secondary outcomes

  1. Ultrasound and pathological indicators related to high-risk plaques

    Ultrasound are used to visualize plaques, combined with pathological examination, to identify the imaging characteristics of high-risk plaques

    Time frame: 0-7days

  2. CT and pathological indicators related to high-risk plaques

    CT are used to visualize plaques, combined with pathological examination, to identify the imaging characteristics of high-risk plaques

    Time frame: 0-7days

  3. MRI and pathological indicators related to high-risk plaques

    MRI are used to visualize plaques, combined with pathological examination, to identify the imaging characteristics of high-risk plaques

    Time frame: 0-7days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2025, 23 months after the start.

Of 79 non-industry observational studies under Carotid Stenosis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 104. This study's planned 23 months is below that.

Counting every sponsor, half of 87 studies reached it within 50 months; a quarter within 30 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2024
First posted
Jan 25, 2024
StartActual
Dec 31, 2023
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 1, 2025
Last update
Jan 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06222983
Responsible party
Sponsor
First posted
Jan 25, 2024
Start date
Dec 31, 2023
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Jan 25, 2024

Study contacts

Lianrui Guo, Dr.
Contact
lianguiguo@sina.com
+8613671009746
Xixiang Gao, Dr.
Contact
vascsurgeon@163.com
: +8613581674309
Lianrui Guo
principal investigator · Xuanwu Hospital, Beijing

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion